<DOC>
	<DOCNO>NCT01385228</DOCNO>
	<brief_summary>The primary purpose define safety tolerability docetaxel/prednisone combination pazopanib ( DPP ) men metastatic Castration Resistant Prostate Cancer ( mCRPC ) .</brief_summary>
	<brief_title>Pazopanib , Docetaxel , Prednisone Prostate</brief_title>
	<detailed_description>This Phase I study consist dose escalation portion include dose escalation phase 10 dose level : ( 1a ) docetaxel 60 mg/m2 , pazopanib 400 mg daily , prednisone 5 mg BID ; ( 2a ) docetaxel 75 mg/m2 , pazopanib 400 mg daily , prednisone 5 mg BID ; ( 3a ) docetaxel 75 mg/m2 , pazopanib 600 mg daily , prednisone 5 mg BID ; ( 4a ) docetaxel 75mg/m2 , pazopanib 800 mg daily , ( 5a ) docetaxel 75mg/m2 , pazopanib 1000mg daily , prednisone 5 mg ; ( 1b ) docetaxel 60 mg/m2 , pazopanib 400 mg daily x 17 day , prednisone 5 mg BID ; ( 2b ) docetaxel 75 mg/m2 , pazopanib 400 mg daily x 17 day , prednisone 5 mg BID ; ( 3b ) docetaxel 75 mg/m2 , pazopanib 600 mg daily x 17 day , prednisone 5 mg BID ; ( 4b ) docetaxel 75mg/m2 , pazopanib 800 mg daily x 17 day , ( 5b ) docetaxel 75mg/m2 , pazopanib 1000mg daily x 17 day , prednisone 5 mg . If investigator see &gt; 1 dose limit toxicity ( DLT ) Dose level 3 investigator would investigate docetaxel 75 mg/m2 , pazopanib 600 mg daily , prednisone 5 mg BID ( Dose level 3a ) . If &lt; 1 DLT see Dose level 3 Pharmacokinetic ( PK ) analysis complete acceptable , investigator proceed dose level 4 ) docetaxel 75 mg/m2 , pazopanib 1000 mg daily , prednisone 5 mg BID . The investigator dose escalate classic 3+3 design . The maximum tolerated dose ( MTD ) define high dose level result 2 dose limit toxicity ( DLTs ) . A dose expansion MTD 10-15 patient ( total 36 patient ) accrue order describe safety profile .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Histologically confirm carcinoma prostate . Histologic evidence may confirm local metastatic biopsy review . Nonadenocarcinomas permit . Radiographic evidence metastatic disease ; nonevaluable , bone metastasis permit . Evidence disease progression despite castrate level testosterone ( &lt; 50 ng/dl ) . At time screen , least 2 week since prior palliative radiation therapy 4 week major surgery , resolution toxic effect prior therapy National Cancer Institute Common Terminology Criteria Adverse Events ( NCICTCAE ) ; version 4.0 Grade &lt; 1 . Age &gt; 18 year Adequate laboratory parameter Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 Life expectancy great 3 month Written , sign date Institutional Review Board ( IRB ) approve informed consent form . History active central nervous system metastases The use immunologic , biologic , hormonal therapy within 2 week study entry . Major surgery , open biopsy , traumatic injury within 4 week screen visit Subjects recover prior biopsy , surgery , traumatic injury , and/or radiation therapy . Previous treatment docetaxel , include neoadjuvant adjuvant set Presence nonhealing wound ulcer Grade 3 great hemorrhage within past month . Uncontrolled hypertension American Heart Association Class 24 heart disease history congestive heart failure ejection fraction &lt; 40 % , recent cardiovascular event ( within 12 month ) include unstable angina , exertional angina , myocardial infarction , exertional rest claudication , stroke/Cerebral Vascular Event/Transient Ischemic Attack . Patients know moderate severe document carotid peripheral vascular disease exclude . Angioplasty stenting coronary peripheral artery exclusionary within past 12 month . Anticoagulation warfarin ( therapeutic dos warfarin catheter patency permit 2 mg/day ) . Low molecular weight heparin permit . Diabetes mellitus glycosylated hemoglobin A1c ( HbgA1c ) &gt; 8 % despite therapy Subjects active autoimmune disorder ( ) treat systemic immunosuppressive agent within 4 week prior screen visit . Active infection ( ) , active antimicrobial therapy serious intercurrent illness . Does agree use medically acceptable contraceptive method study 3 month last dose pazopanib . Any major medical psychiatric illness , investigator 's judgment , substantially increase risk associate subject 's participation study , include inability absorb oral medication . Known hypersensitivity component docetaxel infusion medical reason able receive adequate premedication ( example , antihistamine antiinflammatory agent ) . CalculatedQT ( QTc ) interval baseline EKG &gt; 500milliseconds History presence nephrotic syndrome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>pazopanib</keyword>
	<keyword>docetaxel</keyword>
	<keyword>metastatic prostate cancer</keyword>
</DOC>